Eli Lilly's Ebglyss gains FDA approval for atopic dermatitis treatment, poised to rival Dupixent with strong performance in ...

An NHS paediatrician sent a WhatsApp message offering children and parents £1,500 to take part in Moderna’s Phase III ...

Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

Eli Lilly and Almirall have announced positive long-term results for their targeted IL-13 inhibitor Ebglyss ...

Eli Lilly and Company has announced new long-term data from the ADjoin extension study, demonstrating that EBGLYSS ...

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs ...

(RTTNews) - Eli Lilly and Company (LLY) Wednesday reported new long-term data for its atopic dermatitis treatment Ebglyss. The results were reported from ADjoin long-term extension study.

Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and ...

Jefferies analyst Michael Yee in a note to investors called rocatinlimab’s atopic dermatitis data “modest,” noting that the ...

Eli Lilly has received approval in Japan for Kisunla (donanemab-azbt) to treat early symptomatic Alzheimer's disease.

Real-time index price for TSX Composite Index (TXCX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...